Milrinon Hikma (Milrinone)

• Milrinone acts as a cardiac inotropic and vasodilator, improving cardiac output in acute heart failure states.
• Acute decompensated heart failure: enhances myocardial contractility and reduces afterload to improve symptoms.
• Cardiogenic shock: provides rapid inotropic support to stabilize hemodynamics.
• Low cardiac output syndrome: increases cardiac output when conventional therapy is insufficient.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes, preventing the breakdown of cyclic adenosine monophosphate (cAMP) within cardiac myocytes and vascular smooth muscle. Elevated intracellular cAMP enhances calcium influx, producing a positive inotropic effect, while simultaneously promoting vasodilation through smooth‑muscle relaxation, thereby improving cardiac output and reducing systemic vascular resistance.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypotension: reduced blood pressure due to vasodilation.
• Headache: often associated with lowered vascular tone.
• Tachyarrhythmia: increased heart rate or irregular rhythm.
• Nausea: gastrointestinal discomfort.
• Flushing: warm sensation and reddening of skin.
• Diarrhea: loose stools in some patients.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening heart rhythm disturbances.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Thrombocytopenia: low platelet count leading to bleeding risk.
• Anaphylactic reactions: rare severe allergic response.
• Death: possible in cases of profound hemodynamic collapse.

• Milrinone requires careful monitoring and specific safety measures.
• Monitor blood pressure: watch for hypotension and adjust infusion rate.
• Observe cardiac rhythm: detect arrhythmias promptly.
• Assess renal function: dose may need adjustment in renal impairment.
• Avoid use in severe aortic stenosis: risk of excessive vasodilation.
• Contraindicated in known hypersensitivity: discontinue if allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Concurrent phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma levels, raising toxicity risk.
• Other potent inotropes: synergistic action can precipitate dangerous arrhythmias.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt the desired inotropic response, requiring dose titration.
• Diuretics: volume depletion can exacerbate hypotension.
• Digoxin: combined use may increase risk of arrhythmias; monitor serum levels.